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Myotonia is a symptom of various genetic and acquired skeletal muscular disorders and is
characterized by hyperexcitability of the sarcolemma. Here, we have performed a comparative
proteomic study of the genetic mouse models ADR, MTO and MTO*5J of human congenital
myotonia in order to determine myotonia-specific changes in the global protein complement
of gastrocnemius muscle. Proteomic analyses of myotonia in the mouse, which is caused by
mutations in the gene encoding the muscular chloride channel Clc1, revealed a generally
perturbed protein expression pattern in severely affected ADR and MTO muscle, but less
pronounced alterations in mildly diseased MTO*5J mice. Alterations were found in major
metabolic pathways, the contractile machinery, ion handling elements, the cellular stress
response and cell signaling mechanisms, clearly confirming a glycolytic-to-oxidative
transformation process in myotonic fast muscle. In the long-term, a detailed biomarker
signature of myotonia will improve our understanding of the pathobiochemical processes
underlying this disorder and be helpful in determining how a single mutation in a tissue-specific
gene can trigger severe downstream effects on the expression levels of a very large number
of genes in contractile tissues.
Introduction
A distinct group of skeletal muscular disorders is represented by
ion channelopathies. These diseases of the voluntary contractile
system are characterized by recurrent patterns of mutations,
whereby primary abnormalities in Cl-, Na+-, K+- or Ca2+-
channels are associated with hyperexcitability causing myotonia,
hypoexcitability leading to periodic paralysis, or susceptibility
to the pharmacogenetic disorder malignant hyperthermia.1
The subgroup of myotonias and paramyotonias is classified
as hereditary muscle diseases in which involuntary contractions
are caused by hyperexcitability of the muscle fibre plasmalemma.2
Hyperexcitability can be caused either by lowered Cl-
conductance (myotonias) or by prolonged activity of Na+-
channels (paramyotonias).3 Nondystrophic myotonias are
closely related to ion channel dysfunction, and are classified as
channelopathies affecting muscle-specific Cl- or Na+-channels.4
Mutations in the gene encoding the muscle Na+-channel are
associated with paramyotonia congenita, potassium-sensitive
myotonia and hyperkalemic periodic paralysis with myotonia.
In contrast, nondystrophic chloride channelopathies are
responsible for myotonia congenita, recessive Becker myotonia
and dominant Thomsen myotonia.5
Genetic animal models of neuromuscular diseases are widely
used for studying the molecular pathogenesis of inherited
disorders, evaluating the effects of drug treatment on disease
progression and testing of novel therapeutic strategies such as
stem cell transfer or gene therapy.6 In the case of myotonia
research, the muscle-specific manifestation7 and molecular basis8
of this disorder has been clarified by the analysis of a myotonic
mouse mutant,9 the ADR mouse (phenotype ADR, genotype
Clc1adr/adr).10 Myotonia in the mouse is caused by insertional
(allele adr8), nonsense (allele mto11) or missense (allele adr*K)11
mutations at the gene locus Clc1 (chromosome 6) for the
muscular chloride channel ClC-1. In human myotonia, a large
number of both recessive (type Becker) and dominant (type
Thomsen) mutations at the gene locus CLCN1 (chromosome 7)
have been identified.4 The myotonic ADR and MTO mice are
both genocopies and phenocopies of human congenital
myotonias. The more pronounced phenotype makes them ideal
model systems for studying secondary effects of myotonia on the
skeletal muscle proteome. However, it is important to keep in
mind that mice exhibit a higher prevalence of fast-glycolytic fibres
in the majority of muscles as compared to humans.
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Prior to the molecular elucidation of mouse myotonias, a
variety of biochemical changes have been described in affected
muscles10,12 that represent downstream effects of the hyper-
excitability of myotonic muscle.13–18 Many of these biochemical
changes were reminiscent of those observed in chronic low-
frequency stimulated fast muscle19 which involves a fibre type
shift from fast-glycolytic white muscle to fast-oxidative red
muscle.13,14 In long-term electrostimulated fast rabbit muscles,
fibre transitions eventually result in a slow-oxidative muscle
phenotype that is reflected by extensive fast-to-slow switches
in protein isoforms.19 In myotonic muscles, transformations
are well documented by the alterations in the isoform expression
pattern of slow and heavy chains of muscle myosins. For
example, hyperexcitability triggers a reduced phosphorylation
of the fast myosin light chain MLC2f14 and a lower
concentration of myosin heavy chain isoform MyHC-IIB in
myotonic fast muscles.18 However, since previously documented
changes in myotonic mouse muscle have been established by
classical histochemical, protein biochemical, immunological
and mRNA quantification methods, these technologies may
have overlooked more subtle changes in the global protein
pattern. In this respect, mass spectrometry-based proteomics
suggests itself as a large-scale and high-throughput analytical
tool to complement traditional biochemical and histochemical
studies of myotonic animal models.
Here, we have carried out a comparative proteomic survey
of ADR vs. MTO muscle preparations. In addition we have
included the characterization of a new allele, mto*5J, at the
Clc1 locus of the mouse which allows for a longer survival of
the affected homozygous animals. The milder phenotype of
MTO*5J mice is clinically closer to human congenital myotonia.
In the present work we have attempted a broad proteomics-
based analysis to determine a more complete spectrum of
changes caused by a single, well defined gene mutation by
means of a changed physiological activity of the organ in
which this gene is expressed, skeletal muscle. Comparative
immunoblotting of the myotonic muscles from the animal
models ADR, MTO and MTO*5J confirmed previously
reported myotonia-specific changes and proteomic profiling
revealed a generally perturbed protein expression pattern in
the severely affected ADR and MTO muscle, but less
pronounced alterations in mildly diseased MTO*5J mice.
The proteomic identification of hitherto undetected changes
contributes to an improved understanding of the overall
pathobiochemical processes in myotonic muscle.
Materials and methods
Materials
Electrophoresis-grade chemicals, immobilized pH gradient strips
of pH 4–7 and pH 6–11, IPG buffers for isoelectric focusing and
acetonitrile were purchased from Amersham Biosciences/GE
Healthcare (Little Chalfont, Bucks., UK). Acrylamide stock
solutions were obtained as ultrapure protogel mixtures from
National Diagnostics (Atlanta, GA, USA). Protein molecular
weight standards, Laemmli-type gel buffers, Coomassie Blue
dye and Bradford reagent for protein quantification were
from Biorad Laboratories (Hemel-Hempstead, Herts., UK).
Protease inhibitors and chemiluminescence substrate were
purchased from Roche Diagnostics (Mannheim, Germany).
Ruthenium batho-phenanthrolinedisulfonate chelate for the
production of RuBPs dye was from Reagecon Diagnostic
Limited (Shannon, Ireland). Sequencing grade-modified
trypsin was obtained from Promega (Madison, WI, USA).
LC-MS Chromasolv water and formic acid were from Fluka
(Dorset, UK). Nitrocellulose transfer stacks were obtained
from Invitrogen (CA, USA). X-Ray film was from Fuji Photo
Film (Tokyo, Japan). Antibodies were purchased from
Abcam, Cambridge, UK (ab7785 to tropomyosin; ab11427
to parvalbumin; ab2480 to the phosphorylatable form of
myosin light chain; ab28777 to the voltage-dependent ion
channel VDAC1; ab48003 to myosin light chain MLC2),
Sigma, Dorset, UK (M8648 to myoglobin), Upstate Biotech-
nology, Lake Placid, NY (mAb 05-298 to a-dystroglycan) and
Affinity Bioreagents, Golden, CO, USA (MA3912 to fast
SERCA1 Ca2+-ATPase; MA3919 to slow/cardiac SERCA2
Ca2+-ATPase). All secondary antibodies were from Chemicon
International (Temecula, CA, USA). Ponceau S-Red staining
solution, DNase-I and all general chemicals were obtained
from Sigma Chemical Company (Dorset, UK).
Genetic mouse models of myotonia
Three allelic mutations at the gene locus Clc1 coding for the
muscular chloride channel ClC-1 were used in this study:
Mice carrying the adr allele (Clc1adr) have been obtained from
Dr D. L. Watts, Guy’s Hospital, London in 1982; the
mutation was on the A2G background; SWR/J mice carrying
themto allele (Clc1mto) were purchased from Jackson Laboratory
(Bar Harbor, Maine, USA) in 1986, whereby the mutation was
subsequently bred into the C57Bl/6 strain. The mto5J allele
(Clc1mto–5J) was discovered at Jackson Laboratory in 2000
during a mutant screen on a 129 background, and allelism to
mto was shown. In the University of Bielefeld, the mutation
was transferred to a C57/BL6 background. Originally, this
strain carried a Fcgr2btm1Ttk (Fc gamma2b receptor = CD32)
transgene, which was later removed by controlled breeding.
Allele adr is due to a transposon insertion in intron 128 which
disrupts normal splicing; mto to a stop codon in codon
47 (R47X);11 mto5J carries a base insertion in codon 75 which
causes a frameshift resulting in a stop codon in position 93. As
expected, all three alleles are null mutations that do not
produce immunologically demonstrable ClC-1 protein.
Whereas the myotonic symptoms are severe in ADR and
MTO mice and cause a considerable weight loss and reduced
life span, MTO*5J mice are only mildly affected, and show less
reduced body weights and near normal life spans. The
physiological and histochemical properties of MTO*5J muscles
are intermediate between those of ADR and wildtype control
muscles. The reason for the exceptionally mild response to a
complete ClC-1 deficiency is not known: removal of the
transgene did not aggravate the myotonia, nor did its
introduction into the MTO mouse lead to a mild phenotype.
Another unusual property of MTO*5J mice is central nuclei in
their muscle fibres indicating ongoing regeneration like in
dystrophic muscle. Further details on the newly described
MTO*5J phenotype are found in the ESI.w
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Preparation of protein extracts from skeletal muscle
Freshly dissected muscle samples were quick-frozen in liquid
nitrogen, transported on dry ice and stored at 80 1C prior to
usage. Frozen gastrocnemius muscle specimens from 11-week
old myotonic ADR, MTO, and MTO*5J mice and normal
control mice were ground, in the presence of liquid nitrogen,
into a fine powder using pestle and mortar. As previously
described in detail,20–22 muscle powder generated from 100 mg
of wet weight tissue was resuspended in 1 ml lysis buffer
containing 7 M urea, 2 M thiourea, 65 mM Chaps and 100 mM
DTT, as well as 1% (v/v) ampholytes pH 4–7 or ampholytes
pH 6–11. In order to eliminate excessive viscosity due to the
presence of DNA, 10 ml of DNase-I was added per 1 ml of lysis
buffer. The lysis buffer was also supplemented with a protease
inhibitor cocktail from Roche Diagnostics (0.2 mM pefabloc,
1.4 mM pepstatin, 0.15 mM aprotinin, 0.3 mM E-64, 1 mM
leupeptin, 0.5 mM soybean trypsin inhibitor and 1 mM EDTA)
to avoid proteolytic degradation of skeletal muscle proteins.
Following incubation for 2.3 h at 4 1C on a thermomixer with
gentle shaking, the suspension was centrifuged at 4 1C for 20
min at 20 000  g. The protein-containing middle layer
was carefully removed. Acetone-precipitated proteins were
resuspended in standard lysis buffer21 and protein concentra-
tion was determined using a commercially available assay kit
from Biorad Laboratories (Hemel-Hempstead, Herts., UK).
Two-dimensional gel electrophoretic analysis of the soluble
muscle proteome
The two-dimensional gel electrophoretic separation of the
urea-soluble protein complement from normal vs. myotonic
gastrocnemius tissues was carried out using a total protein
amount of 500 mg per analytical slab gel. Using a re-swelling
tray from Amersham Biosciences/GE Healthcare (Little Chalfont,
Bucks., UK), IPG strips of pH 4–7 and pH 6–11 were
rehydrated for 12 h with 0.45 ml of a rehydration buffer
containing 7 M urea, 2 M thiourea, 65 mM Chaps, 10 mg ml1
DTT, and 500 mg of muscle protein sample, as well as 1% (v/v)
ampholytes pH 4–7 or ampholytes pH 6–11. As a tracking dye,
the buffer was complemented with 0.05% (w/v) Bromophenol
Blue. Following placement of the first-dimension strips (24 cm
length) gel-side up onto the Ettan IPGphor manifold and
coverage with 108 ml of dry-strip cover fluid, gels were run
on the IPGphor IEF system with the following isoelectric
focusing running conditions: 120 min at 100 V (step and hold),
90 min at 500 V (step and hold), 60 min at 1000 V (step and
hold), 60 min at 2000 V (step and hold), 60 min at 4000 V (step
and hold), 120 min at 6000 V (step and hold), 240 min at
8000 V (step and hold), 180 min at 500 V (step and hold) and
240 min at 8000 V (step and hold). Following first-dimension
separation, gel strips were equilibrated for 30 min. During the
first 20 min of equilibration, the buffer system contained
100 mM dithiothreitol and during the last 10 min of incubation
the equilibration buffer contained 0.25 M iodoacetamide.
Using the EttanDalt-twelve system from Amersham Biosciences/
GE Healthcare (Little Chalfont, Bucks., UK), the gel electro-
phoretic separation of muscle proteins in the second dimension
was performed with standard 12.5% (w/v) slab gels. Following
washing in SDS-containing running buffer, isoelectric focusing
strips were placed on top of second dimension gels and held in
place with a 1% (w/v) agarose sealing gel. Twelve slab gels
were run in parallel at 0.5 W per gel for 60 min and then 15 W
per gel was employed until the blue dye front had disappeared
from the bottom of the gel.
Fluorescent protein labelling with RuBPs dye
Ruthenium II Bathophenathroline Disulfonate Chelate
(RuBPs) staining of slab gels was carried out as previously
described in detail.23 A stock solution of RuBPs dye was
prepared as outlined by Rabilloud et al.24 Slab gels were fixed
overnight in 30% (v/v) ethanol and 10% (v/v) acetic acid and
subsequently washed 4 times with 20% (v/v) ethanol for 30 min.
Gels were stained for 6 h in 20% (v/v) ethanol containing
200 nM of RuBPs dye and then re-equilibrated for 10 min in
distilled water prior to image analysis. Fluorescently labeled
proteins were visualised using a Typhoon Trio variable mode
imager system from Amersham Biosciences/GE Healthcare
(Little Chalfont, Bucks., UK). Gel analysis was performed with
Progenesis SameSpots analysis software from Nonlinear
Dynamics (Newcastle upon Tyne, UK) using the following para-
meters: ANOVA, po 0.05; n= 5; and a power value of Z0.8.20
The 12.5% (w/v) slab gels used in this study separated muscle-
associated proteins ranging in molecular mass from approximately
15 kDa to 220 kDa. Proteins in spots with a significant increase or
decrease in abundance (differing between the various groups
with Z 1.4 fold-change) were identified by mass spectrometry.
Mass spectrometric identification of muscle proteins
Excised protein spots from Coomassie Blue-stained pick gels,
which were matched to RuBPs-labelled master gels, were
employed for the mass spectrometric identification of proteins
of interest. Standardized in-gel tryptic digestion was used for
the generation of representative peptide mixtures.21 Excision,
washing, destaining and treatment with trypsin were
performed by a previously optimized method.22 Trypsin-
generated peptides were harvested by removing supernatants
from digested gel plugs after centrifugation. Further recovery
was achieved by adding 30% acetonitrile/0.2% trifluoroacetic
acid to the gel plugs for 10 min at 37 1C with gentle agitation.
Resulting supernatants were pooled with the initially recovered
peptides following trypsin digestion.21 Samples were dried
through vacuum centrifugation and concentrated peptide
fractions were then suspended in mass spectrometry-grade
distilled water and 0.1% formic acid, spun down through spin
filters and added to LC-MS vials for identification by ion trap
LC-MS analysis. The mass spectrometric analysis of peptides
was carried out with a Model 6340 Ion Trap LC/MS apparatus
from Agilent Technologies (Santa Clara, CA, USA). Separation
of peptides was performed with a nanoflow Aglient 1200 series
system equipped with a Zorbax 300SB C18 analytical reversed
phase column using HPLC-Chip technology. Mobile phases
used were A: 0.1% formic acid, B: 50% acetonitrile and 0.1%
formic acid. Samples were loaded into the enrichment part of the
chip at a capillary flow rate set to 4 ml min1 with a mix of solvent
A and solvent B at a ratio of 19 : 1. Tryptic digests were eluted
with a linear gradient of 5% to 70% solvent B over 6 min, 70%
to 100% solvent B over 1 min, 100% to 5% over 1 min.22
Pu
bl
ish
ed
 o
n 
01
 Ju
ne
 2
01
1.
 D
ow
nl
oa
de
d 
by
 M
ay
no
ot
h 
U
ni
ve
rs
ity
 o
n 
05
/1
0/
20
16
 1
4:
45
:3
8.
 
View Article Online
This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 2480–2489 2483
A 5 min post-time of solvent A was used to remove any potential
carry-over. The capillary voltage was set to 2000 V. The flow and
temperature of the drying gas were 4 l min1 and 300 1C,
respectively. Database searches were carried out with Mascot
MS/MS ion search (Matrix Science, London, UK; NCBI
database, release 20100212). All searches used ‘‘Mus musculus’’
as a taxonomic category and the following parameters: (1) two
missed cleavages by trypsin, (2) mass tolerance of precursor
ions 2.5 Da and product ions 0.7 Da, (3) carboxy-
methylated cysteins fixed modification, and (4) oxidation of
methionine as variable modifiaction, (5) percentage coverage
was set at over 10% and (6) at least 2 matched distinct
peptides. Mascot scores over 48 are listed in Tables S1 to S3
(ESIw). All pI-values and molecular masses of identified
proteins were compared to the relative position of their
corresponding two dimensional spots on analytical slab gels.
Immunoblotting of muscle proteins
In order to verify alterations in the abundance of select muscle
proteins and to confirm the glycolytic-to-oxidative transition
process suggested by our proteomic profiling of myotonic
muscle specimens, immuno-decoration of proteins of interest
was performed by 1D immunoblot analysis.22 Following the
electrophoretic transfer of proteins to nitrocellulose membranes,
sheets were blocked in a milk protein solution for 1 h and then
incubated overnight with gentle agitation with a primary
antibody, sufficiently diluted in blocking solution containing
5% (w/v) fat-free milk powder in phosphate buffered saline
(PBS; 0.9% (w/v) NaCl, 50 mM sodium phosphate, pH 7.4).
Subsequently, blots were washed twice with blocking solution
for 10 min before incubation for 1 h with secondary
peroxidase-conjugated antibodies, diluted in blocking solution.
Following further washing steps with blocking solution and
then two rinsing steps with PBS, antibody-decorated bands
were visualized by the enhanced chemiluminescence method
following the manufacturer’s recommendations. Densitometric
scanning of immunoblots was performed on a Molecular
Dynamics 300S computing densitometer (Sunnyvale, CA, USA)
with Imagequant V3.0 software.22
Results
This proteomic study has focused on the biochemical
establishment of secondary effects of myotonia by analyzing
the urea-soluble protein fraction from hyperexcitable skeletal
muscle. Adult skeletal muscles are mainly composed of
contractile fibres, but blood vessels, nerve fibres, connective
tissue, fatty tissue, the extracellular matrix and the interstitium
also contribute to muscle mass, although, under non-traumatic
conditions, only to a small fraction. Thus, the varying degree
of downstream alterations in the pathophysiology of ADR,
MTO, and MTO*5J mice represents an ideal comparative
system to determine graded myotonia-related shifts in protein
expression patterns in complex muscle tissue. Comparative
gel electrophoresis-based proteomic studies of crude tissue
extracts typically result in the identification of soluble and
relatively abundant protein species. Although two-dimensional
gel electrophoresis is an excellent analytical method for the study
of urea-soluble proteins,25 the presence of certain classes of
proteins is underestimated. This technical limitation has to be
taken into account when one interprets proteomic data from
comparative gel electrophoretic analyses. Underrepresented
proteins include low-molecular-mass proteins, integral
membrane proteins, extremely basic or acid proteins, and
high-molecular-mass proteins.26
Hence, the types of proteins included in this study are urea-
soluble elements that are mostly associated with the contractile
apparatus, metabolic pathways, cellular signaling events and
the cellular stress response. Fig. 1 and 2, as well as Tables S1 to S3
(ESIw), summarize the results of our gel electrophoresis-based
proteomic investigation of potential differences in the secondary
abnormalities of ADR vs. MTO vs. MTO*5J gastrocnemius
muscle. In order to be able to correlate mass spectrometry-
identified protein species listed in individual tables with
distinct 2D protein spots of altered concentration in their
respective gel images, the numbering system of proteins in
tables and gels is identical with respect to ADR muscle
(Fig. 1C and D; Table S1, ESIw), MTO muscle (Fig. 1E and F;
Table S2, ESIw) and MTO*5J (Fig. 1G and H; Table S3,
ESIw). The findings of an immunoblotting survey of alterations
in the abundance of markers of glycolytic-to-oxidative transitions,
as well as changes in select muscle proteins that have been
identified by proteomic analysis, are presented in Fig. 3 and 4.
Proteomic profiling of ADR gastrocnemius muscle
Large-scale and high-resolution 2D gel electrophoresis, in
combination with densitometric analysis using a Typhoon
Trio variable imager and image analysis with Progenesis 2D
analysis software, lead to the identification of 50 muscle-
associated protein spots with a considerable change in
concentration levels in the ADR mouse model of severe
myotonia. A representative master gel with electrophoretically
separated gastrocnemius muscle proteins is shown for the
pH 4–7 and pH 6–11 range in Fig. 1C and D. Muscle proteins
with a myotonia-related alteration in abundance ranged in
molecular mass from apparent 19 kDa (myosin light chain)
to 98 kDa (glycogen phosphorylase) and covered a pI-range
from approximately 4.8 (protein disulfide isomerase) to 9.4
(troponin). The results of the mass spectrometric identification
of the 50 protein species are summarized in Table S1 (ESIw),
which combines data from both pH 4–7 and pH 6–11 gels.
Table S1 (ESIw) lists the protein name, protein accession
number, pI-value, molecular mass, number of matched peptide
sequences, Mascot score, percentage sequence coverage, fold-
change and ANOVA score of individual proteins affected by
myotonia. The majority of identified proteins were shown to be
constituents of the contractile apparatus, major metabolic
pathways, the cellular stress response and various cellular
signaling mechanisms. A reduced concentration was found for
36 muscle proteins and 14 elements were shown to be increased
in their density. The muscle protein species with the highest fold
decrease was identified as the phosphorylatable fast MLC2f
isoform of myosin light chain. In addition to the contractile
protein MLC2f (spots 1, 12, 14–17, 20), triosephosphate
isomerase (spots 2, 3), 40 kDa protein (spot 4), aminoacylase
(spots 5, 13), fast troponin TnI-2 (spots 6, 19), alpha-3 chain of
tropomyosin (spots 7, 9), alpha and beta subunits of actin
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(spots 8, 18, 22), troponin TnT (spots 10, 23, 26, 27), beta
subunit of trifunctional enzyme (spot 11), otubain (spot 21),
aldolase (spot 24), glycogen phosphorylase (spot 25), myosin-
binding protein H (spot 28), four-and-a-half-LIM-domains-1
protein (spot 29), kappa-B motif-binding proteins (spot 30),
isocitrate dehydrogenase (spot 31), prosome (spot 32),
carbonic anhydrase (spot 33), haloacid dehalogenase-like
hydrolase (spot 34), myosin light chain isoform MLC3 (spot 35)
and F-actin capping protein (spot 36) were found to be
decreased in myotonic ADR muscle. In contrast, the muscle
protein species with the highest fold increase was identified as
the enzyme protein disulfide isomerase (spot 50). Other
increased muscle proteins were represented by serpin (spot 49),
heat shock protein Hsp70 (spot 48), alpha subunit of trifunctional
enzyme (spot 47), mitochondrial ATP synthase (spot 46),
alpha actin (spots 43 and 45), slow MLC1s isoform of myosin
light chain (spot 44), albumin (spot 42), cytochrome b-c1
complex (spots 37 and 41), dihydrolipoamide S-acetyltransferase
(spot 40), troponin TnI-2f (spot 39) and ATP-specific succinyl-
CoA synthetase (spot 38).
Proteomic profiling of MTO gastrocnemius muscle
The lower and higher pH-scale of the two different IEF
approaches resulted in the identification of 41 muscle protein
spots with a changed abundance in the MTO mouse. A
representative master gel with electrophoretically separated
gastrocnemius muscle proteins is shown in Fig. 1E and F.
Muscle proteins with a changed concentration covered a
pI-range from approximately 4.6 (tropomyosin) to 7.6
(cofilin) and ranged in molecular mass from apparent 19 kDa
(myosin light chain) to 84 kDa (heat shock protein Hsp90).
Table S2 (ESIw) summarizes the results of the mass spectro-
metric identification of the 41 protein species from MTO
Fig. 2 Overview of alterations in ADR, MTO, and MTO*5J vs. wild
type control muscle. The graphical presentation illustrates major
changes in distinct classes of protein in hyperexcitable muscle tissues
as revealed by mass spectrometry-based proteomics. The solid black
spots represent MS-identified proteins with a changed abundance in
MTO muscle preparations. Values for ADR muscle (triangles) and
MTO*5J muscle (squares) are superimposed by their concentration
relative to wild type muscle. Components belonging to the contractile
apparatus, the glycolytic pathway, oxidative metabolism or the
cellular stress response are marked by blue, green, red and purple
symbols, respectively.
Fig. 1 Two-dimensional gel electrophoretic analysis of gastrocnemius
muscle from the ADR, MTO and MTO*5J mouse model of myotonia.
Shown are RuBPs-labelled master gels of muscle preparations for the pH
4–7 (A, C, E, G) and pH 6–11 (B, D, F, H) range. Wild type (WT)
muscle is shown in panels A and B. Proteins with a drastically different
expression level are marked by circles and are numbered 1–50 (panels
C and D; ADR), 1–41 (panels E and F; MTO) and 1–12 (panels G and
H; MTO*5J). See Tables S1 to S3 in the ESIw for a detailed listing of
mass spectrometry-identified proteins with a changed abundance in
myotonic ADR, MTO and MTO*5J muscle, respectively. The
pH-values of the first dimension gel system and molecular mass
standards (in kDa) of the second dimension are indicated on the top
and on the left of the panels, respectively.
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muscle tissue. In analogy to the above-described proteins in
ADR muscle, the majority of identified proteins in MTO
preparations were shown to be constituents of major metabolic
reactions, the contractile machinery, the cellular stress response
and cell signaling pathways. An increased concentration was
shown for 15 muscle proteins and 26 components were found to
be decreased. As already shown for ADR muscle, the protein
species with the strongest reduction was the phosphorylatable
fast MLC2f isoform of myosin light chain. Decreased proteins
were identified as MLC2f (spots 1, 7, 8, 10, 14, 17, 20, 24), DJ-1
protein (spot 2), heat shock protein beta-7 (spot 3), myosin-
binding protein H (spot 4), T complex protein 1 (spot 5),
myosin light chain MLCs (spot 6), creatine kinase (spot 9),
ribonuclease/angiogenin inhibitor (spot 11), glycogenin (spot 12),
tropomyosin (13), heat shock protein Hsp-2 (spot 15), myosin
light chain MLC3 (spot 16), glyceraldehyde-3-phosphate
dehydrogenase (spot 18), F-actin capping protein (spot 19),
triosephosphate isomerase (spot 21), protein disulfide isomerase
(spot 22), pyruvate kinase (spots 23 and 25) and sepiapterin
reductase (spot 26). In contrast, phosphoglucomutase (spot 41)
was shown to be the enzyme with the highest fold increase in
MTO muscle. In addition, succinate dehydrogenase (spot 40),
Actg2 protein (spot 39), cofilin (spot 38), troponin TnTf (spot 37),
alpha actin (spots 35 and 36), mitochondrial NADH
dehydrogenase (spot 34), heat shock protein Hsp90 (spot 33),
cytosolic malate dehydrogenase (spot 32), 14-3-3 protein (spot 31),
tubulin (spot 30), UTP-glucose-1-phosphate uridyltransferase
(spot 29), one specific subspecies of MLC2f (spot 28) and
dihydrolipoamide-S-acetyltransferase (spot 27) were increased
in MTO gastrocnemius muscle.
Proteomic profiling of MTO*5J gastrocnemius muscle
In stark contrast to ADR and MTO muscles, the proteomic
profiling of MTO*5J preparations showed considerably less
changes in the degree and number of proteins. As illustrated in
Fig. 1G and H, only 12 muscle protein spots with a changed
abundance were identified in the MTO*5J mouse model of
mild myotonia. Proteins with a changed concentration covered
a pI-range from approximately 4.8 (myosin light chain
MLC2f) to 9.2 (F1-ATP synthase) and ranged in molecular
Fig. 3 Immunoblotting survey of skeletal muscle proteins with a
differential expression pattern in myotonic muscle. The figure
summarizes the analysis of skeletal muscle markers characteristic of
a glycolytic-to-oxidative transformation process and the verification of
MS-identified proteins with a changed concentration in myotonic
gastrocnemius muscle. Shown is an expanded view of immuno-
decorated bands from normal, ADR, MTO and MTO*5J preparations,
representing a-dystroglycan (a-DG; as loading control), parvalbumin
(PVA), the fast SERCA1 and slow SERCA2 isoform of the sarco-
plasmic reticulum Ca2+-ATPase, the voltage-dependent anion channel
VDAC1, the oxygen carrier myoglobin (MYO), fast MLC2f isoform
of myosin light chain, the phosphorylatable form of fast myosin light
chain (MLC2f-P), the glycolytic enzyme triosephosphate isomerase
(TPI) and the contractile protein tropomyosin (TM). Lanes 1 and 2
show control (C) and myotonic (M) preparations, respectively.
Fig. 4 Verification of select proteomic data by immunoblotting. The
comparative immunoblot analysis presented in Fig. 3 was statistically
evaluated using an unpaired Student’s t-test (n = 5; *p o 0.05;
**po 0.01; ***po 0.001). The analysis of ADR, MTO and MTO*5J
preparations is shown for the MLC2f isoform of myosin light chain
(A–C), the phosphorylatable form of myosin light chain (MLC2f-P)
(D–F), the glycolytic enzyme triosephosphate isomerase (TPI) (G–I)
and the contractile protein tropomyosin (TM) (J–L). Lanes 1 and 2
show control (C) and myotonic (M) preparations, respectively.
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mass from apparent 19 kDa (myosin light chain) to 61 kDa
(heat shock protein Hsp60). Table S3 (ESIw) lists the names
and fold-changes of the identified proteins, with 4 proteins
being decreased and 8 proteins being increased in MTO*5J
samples. While myosin heavy chain MHC1 (spot 1), myosin
light chain MLC2f (spot 2), T complex protein 1 (spot 3) and
heat shock protein Hsp60 (spot 4) were shown to be reduced,
protein spots representing troponin TnTf (spots 6 and 12),
triosephosphate isomerase (spot 11), desmin (spot 10),
F1-ATP synthase (spot 9), NADH dehydrogenase (spot 8),
heat shock protein Hsp27 (spot 7) and superoxide dismutase
(spot 5) were found to be increased in MTO*5J specimens.
Overview of alterations in ADR vs. MTO vs. MTO*5J muscle
The graphical presentation of Fig. 2 gives an overview of
major changes in distinct classes of protein in hyperexcitable
muscle tissues as revealed by mass spectrometry-based
proteomics. The solid black spots represent MS-identified
proteins with a changed abundance in MTO muscle preparations.
Since spot numbers and identified protein species do not
correlate between individual sets of experiments (MTO vs.
ADR vs. MTO*5J), the data from the other two mutants are
superimposed by their concentration relative to wild type
muscle. Data from ADR and MTO*5J tissue are shown by
triangles and squares, respectively. Proteins belonging to the
contractile apparatus, the glycolytic pathway, oxidative
metabolism or the cellular stress response are marked by blue,
green, red and purple symbols, respectively. The graph clearly
visualizes the considerable reduction in the MLC2f isoform of
myosin light chain and the metabolic trend of a glycolytic-to-
oxidative transformation, as well as an increased cellular stress
response in hyperexcitable muscles. The direct comparison of
the 3 mutants also shows that the concentration changes in
proteins are more pronounced in the severe MTO and ADR
phenotypes as compared to the milder MTO*5J mouse.
Immunoblot analysis of muscle transformation in myotonia
Following the proteomic profiling of ADR, MTO and
MTO*5J muscle specimens, it was essential to verify changes
in select muscle proteins, as well as confirm the suggested
glycolytic-to-oxidative transformation process in myotonic
muscles. Immunoblotting with isoform-specific antibodies
was used to determine potential changes in the protein expression
profile of markers from the contractile apparatus, the regulatory
machinery of excitation–contraction–relaxation cycle and
energy metabolism. Antibody labeling of the surface protein
a-dystroglycan was used to establish equal loading of muscle
samples. Fig. 3 clearly confirms a general tendency of
myotonic muscles to change to a more aerobic-oxidative
phenotype in a slower-twitching fibre population. In order to
correlate our immunoblotting survey to previously published
work,12 antibody labeling of parvalbumin, a well characterized
high-affinity Ca2+-binding protein of the sarcoplasm
from fast-twitch muscle in small mammalians, was shown
to be greatly reduced in ADR and MTO muscle but its
concentration was only marginally affected in MTO*5J. Fibre
type-specific markers of the regulatory elements of muscle
relaxation, i.e. Ca2+-ATPase isoforms SERCA1 and SERCA2,
exhibited a shift from fast to slow characteristics. In addition a
mitochondrial marker, VDAC1, and a marker of increased
oxidative metabolism, myoglobin, were both found to be
elevated in ADR and MTO mutants, but not significantly
changed in the MTO*5J mouse.
In order to verify key findings from our proteomic screening
of myotonic muscle preparations, 4 proteins with a changed
abundance were further investigated by immunoblotting. As
illustrated in Fig. 3, the MLC2f isoform of myosin light chain
and the phosphorylatable MLC2f protein are greatly reduced
in ADR and MTO muscle, but only marginally affected in
MTO*5J preparations. This clearly confirms the proteomic
findings of a reduced abundance of these contractile elements
in severely myotonic muscle tissues. In addition, the remodeling
of the contractile machinery, as suggested by our proteomic
data, was confirmed by the abundance changes in tropomyosin
in ADR and MTO preparations. Tropomyosin was shown to
be considerably reduced in severely myotonic muscles. Altered
expression levels of metabolic markers of anaerobic metabolism
also agreed with the overall findings of the proteomic profiling
of myotonic muscle. In the severely myotonic animal models
ADR and MTO, a drastic decrease in the glycolytic enzyme
triosephosphate isomerase was established by immunoblotting.
The graphical presentation of the statistical analysis of changes in
myosin light chain isoform MLC2f, the phosphorylatable form
of MLC2f, triosephosphate isomerase and tropomyosin is shown
in Fig. 4.
Discussion
Myotonias are intrinsic disorders of skeletal muscle7 and
characterized by uncontrolled hyperexcitability of voluntary
fibres.3 Since long-termmuscle activity influences the concentration
of many proteins in contractile fibres,27–30 it was of interest to
study potential global changes in the skeletal muscle proteome
due to myotonic pathology. The comparative proteomic profiling
of the myotonic animal models ADR, MTO and MTO*5J
clearly revealed a drastically perturbed protein expression
pattern in the severely affected ADR and MTO muscle, but
only moderate changes in mildly diseased MTO*5J animals.
Hence, the severity of myotonic symptoms appears to correlate
well with the quantitative and qualitative alterations in the
protein complement of ADR and MTO vs. MTO*5J muscle
tissues. Skeletal muscles from the ADR and MTO phenotype
appear to be associated with considerable myotonia-related
changes in proteins involved in the excitation–contraction–
relaxation cycle, energy metabolism, ion handling, stress response
and cellular signaling. A striking feature in both animal
models was the drastic decrease in almost all subspecies of
the phosphorylatable fast MLC2f isoform of myosin light
chain, which agrees with previous biochemical studies of the
ADR mouse.12,14,15
Drastic reduction in fast myosin light chain MLC2f
Previous proteomic studies have shown that isoform changes
in myosin light chains represent reliable markers of muscle
transformation.31 Chronic low-frequency stimulation of fast
rabbit muscle triggers a significant decrease in various
MLCf molecules and an increase in slower counterparts.20,32
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A drastic increase of slow myosin light chain MLC2s was
observed in senescent rat skeletal muscle, which is indicative of
an increased slow fibre population in sarcopenia of old age.33
In analogy, the reduced density of 7, 8 and 1 subspecies of
MLC2f in ADR, MTO and MTO*5J muscle preparations,
respectively, strongly suggests a partial fast-to-slow transition
process in myotonia. In addition, this finding confirms the idea
that enhanced neuromuscular activity regulates the abundance
of this contractile protein.14 Proteomics revealed a concomitant
4-fold increase in the slow MLC1s isoform of myosin light
chain in ADR muscle. Thus, myotonia is clearly associated
with a distinct muscle transformation process. Differential
effects on troponins and a reduction of tropomyosin, F-actin
capping protein and myosin-binding protein H in MTO and
ADR muscle tissue agree with the idea of a myotonia-induced
process of extensive fibre remodeling.
Myotonia-related changes in metabolic enzymes
Many metabolic enzymes are thought to be multi-functional,34
which makes the proteomic interpretation of differential
changes in glycolytic enzymes, mitochondrial components
and metabolite transporters sometimes difficult.35 Despite
the fact that these biochemical facts have to be properly taken
into account, the present study clearly showed a general trend
of decreased glycolytic and anaerobic markers vs. an increase
in mitochondrial and oxidative indicator molecules in myotonia.
The decrease in triosephosphate isomerase, aldolase and
glycogen phosphorylase on the one hand and a concomitant
increase in mitochondrial ATP synthase, albumin, isocitrate
dehydrogenase dihydrolipoamide S-acetyltransferase, ATP-specific
succinyl-CoA synthetase and cytochrome b-c1 complex in
ADR suggested a reduced utilization of glucose and increased
fatty acid oxidation and mitochondrial metabolism. In analogy,
a decrease in glyceraldehyde-3-phosphate dehydrogenase,
triosephosphate isomerase and pyruvate kinase and an increase
in succinate dehydrogenase, NADH dehydrogenase and albumin
in MTO agreed with a myotonia-dependent glycolytic-to-
oxidative transition mechanism. However, there was an
increase in phosphoglucomutase, which might be due to the
multi-functional nature of this glycolytic element.34
Muscle type transformation in myotonia
Immunoblotting supported major findings of our mass
spectrometry-based proteomic study. Antibody labeling confirmed a
switch from the fast SERCA1 isoform of the sarcoplasmic
reticulum Ca2+-pump to its slower SERCA2 form. This
agrees with the idea of myotonia-induced muscle transformation
at the level of physiological handling of Ca2+-homeostasis.
The comparative immunoblot survey presented here demonstrated
reduced levels of parvalbumin in ADR and MTO tissue that
agrees with previous studies.14,15 A considerably less
pronounced reduction of parvalbumin was observed in the
milder MTO*5J phenotype. Since it is well established that the
parvalbumin content is significantly different between
predominantly glycolytic vs. oxidative fibres,36,37 this cytosolic
Ca2+-binding protein might be employable as a reliable
general marker of the severity of myotonia.15 The striking
red colour of ADR and MTO myotonic gastrocnemius muscles
is probably in large part due to increased myoglobin levels, as
suggested by immunoblotting in this report. This drastic
increase in myoglobin has also been reported to occur in fast
muscle following chronic electro-stimulation,20,32 which
makes this essential oxygen-carrier probably a crucial limiting
factor of the metabolic switch to more oxidative metabolism in
skeletal muscles.38 Hence, distinct isoform switches in fast and
slow subspecies of myosin light chain and partially myosin
heavy chains,18 as well as a drastic decrease in parvalbumin
and a considerable increase in myoglobin and VDAC1 represent
a set of biochemical changes indicative of myotonia.
Potential new biomarkers of myotonia
In addition to the above-discussed alterations in common fibre
type-specific markers, many other interesting changes in
distinct protein species occurred in the myotonic animal models
studied here by proteomics. The decrease of 40 kDa protein,
aminoacylase, otubain, four-and-a-half-LIM-domains-1 protein,
kappa-B motif-binding protein, growth factor receptor bound
protein 2, prosome, carbonic anhydrase and haloacid
dehalogenase-like hydrolase in ADRmuscle indicates impairments
in metabolism of amino groups, deubiquitination, gene
transcription, signal transduction, differentiation, CO2-removal,
and carbon or phosphoryl group transfer. Increases in serpin
and heat shock protein Hsp70 may be associated with changes
in protease inhibition and cellular stress response. These
proteins represent a large number of novel potential biomarkers
for ADR muscle changes. The reduced density of carbonic
anhydrase isoform CA3 could be interpreted as a potential
impairment of the CO2-removal mechanism in myotonia.
Carbonic anhydrase converts CO2 into carbonic acid,
39
therefore its lower expression levels may trigger a reduced
availability of this essential hydration reaction which may
result in harmful levels of CO2 in myotonic fibres. Interestingly,
in the case of the trifunctional enzyme its beta subunit was
reduced and its alpha subunit increased in ADR muscle
preparations. Further biochemical studies are needed to be
able to interpret the effects of these changes on mitochondrial
metabolism.
In MTO muscle, the decrease in heat shock protein beta-7,
T complex protein 1, creatine kinase M-type, ribonuclease/
angiogenin inhibitor, glycogenin, heat shock protein Hsp-2
and sepiapterin reductase indicates a partially reduced activity
of the cellular stress response, the creatine shuttle system,
regulation of neovascularization, glucose metabolism and
amino acid metabolism. The increase in Actg2 protein, heat
shock protein Hsp90, 14-3-3 protein, tubulin, UTP-glucose-1-
phosphate uridyltransferase might also be of considerable
importance for the future establishment of a comprehensive
biomarker signature of myotonia. The elevated levels of these
muscle-associated elements could trigger changes in actin
organization, cellular stress response, DNA replication,
microtubular assembly and glucose metabolism. The enzyme
protein disulfide isomerase was shown to be increased in ADR
muscle, but decreased in MTO, and could thus be potentially
used as a differentiating marker of these two different myotonic
phenotypes. This thiol-disulfide oxidoreductase of the sarco-
plasmic reticulum catalyzes the exchange of a disulfide bond
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with substrates thereby facilitating correct protein folding.40
The mildest phenotype studied, gastrocnemius muscle from
MTO*5J mice, showed only a moderate decrease in myosin
heavy chain MHC1, myosin light chain MLC2f, T complex
protein 1 and heat shock protein Hsp60 and an increase in
troponin TnTf, triosephosphate isomerase, desmin, F1-ATP
synthase, NADH dehydrogenase, heat shock protein Hsp27
and superoxide dismutase. This finding indicates that the
milder disease progression is associated with less pronounced
downstream effects on the global muscle protein complement.
Limitations of gel electrophoresis-based proteomics
Since the concentration range of proteins is not a static entity,
but highly dynamic, and because the density of proteins spans
several orders of magnitude in complex cellular systems, no
biochemical technique is capable of determining concentration
changes in all components belonging to a given proteome.
Therefore, studies on urea-soluble muscle proteins by two-
dimensional gel electrophoresis, as described here, focus
mostly on proteins that are associated with the contractile
apparatus, metabolic pathways and the cellular stress
response. Proteins such as myosin heavy chains, parvalbumin
and the muscular chloride channel were not covered in our
2D gel electrophoretic approach probably due to their high
molecular mass, low molecular mass or low abundance,
respectively. In addition, the densitometric analysis of highly
abundant proteins is often complicated by excessive streaking
and cross-contaminations between crowded spot regions.
Multiple spots of the same protein species may be due to
primary products of slightly different isogenes or because of
secondary modifications, such as phosphorylation.
Conclusion
Over the last few years, mass spectrometry-based proteomics
has been applied to the large-scale study of fibre-associated
changes in established animal models of myogenesis, muscle
differentiation, muscular disorders and natural aging.31 In
analogy, here we have analysed the myotonic mouse models
ADR, MTO and MTO*5J using fluorescent 2D gel electro-
phoresis and mass spectrometry to identify novel protein
markers of myotonia-related changes. Myotonia appears to
trigger considerable changes in many elements of the contractile
apparatus, cellular processes and muscle energy metabolism.
A detailed biochemical, cell biological and physiological
characterization of these new biomarkers in the future will
hopefully improve our general understanding of the molecular
pathogenesis of myotonia. Fig. 5 summarizes major events in
the molecular pathogenesis of myotonia and key findings from
our proteomic survey. Destabilization of the membrane
potential due to the loss of sarcolemmal Cl conductance
triggers hyperexcitability of skeletal muscle fibres in myotonia.
Muscle cramps and drastically increased intracellular Ca2+
levels, resulting from unscheduled bursts of action potentials,
Fig. 5 Myotonia: from single gene defect to a plethora of secondary changes in the skeletal muscle phenotype. A single nucleotide replacement or
other event at the DNA level in the Clc1 gene is sufficient to cause loss of function of the muscular chloride channel ClC-1. In mammals, ClC-1 is
expressed in the sarcolemma of mature skeletal muscle, and is required for normal function. Loss of sarcolemmal Cl conductance destabilizes the
membrane potential and leads to hyperexcitability of the muscle fibre, the hallmark of myotonia (generalized myotonia in humans). Unscheduled
bursts of action potentials cause bursts of intracellular Ca2+ release and cramps. Elevated intracellular Ca2+ activates Ca2+-dependent signalling
pathways, e.g. those involving calmodulin/calcineurin and NFAT (nuclear factor of activated T-cells), as shown for the genes for myosin heavy
chains. In myotonic mouse muscles, there is a fibre type shift from fast glycolytic (type IIB) to fast oxidative (type IIA), partially even to type I
(slow) involving changes in key metabolic enzymes and Ca2+-handling proteins like parvalbumin. Presumably due to cramps and imbalance of
gene expression, there is a considerable cellular stress response in myotonic muscle fibres. Dashed arrows symbolize pathways that are not well
characterized.
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cause an increased cellular stress response and activation of
Ca2+-dependent signalling pathways, respectively.41,42 Fibre
type shifting and increased expression levels of mitochondrial
enzymes in myotonic mouse muscles were confirmed by
proteomics. Fibre type transitions from fast-glycolytic to
fast-oxidative fibres are concomitant with altered concentrations
in glycolytic enzymes, mitochondrial components and Ca2+-
handling proteins.13–18 An increased density of mitochondria
and satellite cells was previously reported in myotonic
muscle.43 Myotonia appears to have differential effects on
various elements of the cellular stress response. Proteomics
clearly revealed elevated levels of the molecular chaperones
Hsp27, Hsp70 and Hsp90 in affected muscle tissue. In
conclusion, our proteomic profiling study has shown that a
single mutation in a muscle-specific gene that triggers hyper-
excitability of the sarcolemma has severe downstream effects
on the expression levels of a very large number of genes in
contractile tissues, showing the extreme complexity of gene
regulation in skeletal muscle.
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